Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation

Pharmaceutics

Volumn 4, Issue 3, 2012, Pages 442-478

  Barnes, Stephanie L ^a,b   Whisenant, Jennifer G ^a,c   Loveless, Mary E ^a   Yankeelov, Thomas E ^a,b,c,d,e  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

cancer; DCE MRI; diffusion; FDG; FLT; FMISO; mouse

Indexed keywords

EID: 84907799404     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics4030442     Document Type: Review

References (168)

1. Weis S.M. Cheresh D.A. Tumor angiogenesis: Molecular pathways and therapeutic targets Nat. Med. 2011 17 1359 1370
2. Ferrara N. Gerber H. LeCouter J. The biology of vegf and its receptors Nat. Med. 2003 9 669 676 10.1038/nm0603-669
3. Young R. Reed M. Anti-angiogenic therapy: Concept to clinic Microcirculation 2012 19 115 125 10.1111/j.1549-8719.2011.00147.x
4. Vredenburgh J.J. Desjardins A. Herndon J.E. Dowell J.M. Reardon D.A. Quinn J.A. Rich J.N. Sathornsumetee S. Gururangan S. Wagner M. et al. Phase ii trial of bevacizumab and irinotecan in recurrent malignant glioma Clin.Cancer Res. 2007 13 1253 1259 10.1158/1078-0432.CCR-06-2309
5. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. Berlin J. Baron A. Griffing S. Holmgren E. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 2004 350 2335 2342 10.1056/NEJMoa032691
6. Miller K. Wang M. Gralow J. Dickler M. Cobleigh M. Perez E.A. Shenkier T. Cella D. Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N. Engl. J. Med. 2007 357 2666 2676 10.1056/NEJMoa072113
7. Saltz L.B. Clarke S. Diaz-Rubio E. Scheithauer W. Figer A. Wong R. Koski S. Lichinitser M. Yang T.S. Rivera F. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase iii study J. Clin. Oncol. 2008 26 2013 2019
8. Friedman H.S. Prados M.D. Wen P.Y. Mikkelsen T. Schiff D. Abrey L.E. Yung W.K. Paleologos N. Nicholas M.K. Jensen R. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 2009 27 4733 4740
9. Miles D.W. Chan A. Dirix L.Y. Cortes J. Pivot X. Tomczak P. Delozier T. Sohn J.H. Provencher L. Puglisi F. et al. Phase iii study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J. Clin. Oncol. 2010 28 3239 3247
10. Robert N.J. Dieras V. Glaspy J. Brufsky A.M. Bondarenko I. Lipatov O.N. Perez E.A. Yardley D.A. Chan S.Y. Zhou X. et al. Ribbon-1: Randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J. Clin. Oncol. 2011 29 1252 1260
11. Demetri G.D. van Oosterom A.T. Garrett C.R. Blackstein M.E. Shah M.H. Verweij J. McArthur G. Judson I.R. Heinrich M.C. Morgan J.A. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial Lancet 2006 368 1329 1338
12. Escudier B. Eisen T. Stadler W.M. Szczylik C. Oudard S. Siebels M. Negrier S. Chevreau C. Solska E. Desai A.A. et al. Sorafenib in advanced clear-cell renal-cell carcinoma N. Engl. J. Med. 2007 356 125 134 10.1056/NEJMoa060655
13. Llovet J.M. Ricci S. Mazzaferro V. Hilgard P. Gane E. Blanc J.F. de Oliveira A.C. Santoro A. Raoul J.L. Forner A. et al. Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 2008 359 378 390
14. Motzer R.J. Hutson T.E. Tomczak P. Michaelson M.D. Bukowski R.M. Oudard S. Negrier S. Szczylik C. Pili R. Bjarnason G.A. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J. Clin. Oncol. 2009 27 3584 3590
15. Motzer R.J. Hutson T.E. Tomczak P. Michaelson M.D. Bukowski R.M. Rixe O. Oudard S. Negrier S. Szczylik C. Kim S.T. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 2007 356 115 124
16. Tofts P.S. Brix G. Buckley D.L. Evelhoch J.L. Henderson E. Knopp M.V. Larsson H.B.W. Lee T.Y. Mayr N.A. Parker G.J.M. et al. Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted mri of a diffusable tracer: Standardized quantities and symbols J. Magn. Reson. Imag. 1999 10 223 232 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
17. Yankeelov T.E. Gore J.C. Dynamic contrast enhanced magnetic resonance imaging in oncology: Theory, data, acquisition, analysis, and examples Curr. Med. Imag. Rev. 2007 3 91 107 10.2174/157340507780619179
18. Lee L. Sharma S. Morgan B. Allegrini P. Schnell C. Brueggen J. Cozens R. Horsfield M. Guenther C. Steward W. et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (vegf) receptor inhibitor, ptk787/zk 222584 (ptk/zk): Translation of biological activity in a mouse melanoma metastasis model to phase i studies in patients with advanced colorectal cancer with liver metastases Cancer Chemother. Pharmacol. 2006 57 761 771 10.1007/s00280-005-0120-6
19. Beauregard D.A. Thelwall P.E. Chaplin D.J. Hill S.A. Adams G.E. Brindle K.M. Magnetic resonance imaging and spectroscopy of combretastatin a4 prodrug-induced disruption of tumour perfusion and energetic status Br. J. Cancer. 1998 77 1761 1767 10.1038/bjc.1998.294
20. Maxwell R.J. Wilson J. Prise V.E. Vojnovic B. Rustin G.J. Lodge M.A. Tozer G.M. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced mri NMR Biomed. 2002 15 89 98 10.1002/nbm.754
21. Robinson S.P. McIntyre D.J.O. Checkley D. Tessier J.J. Howe F.A. Griffiths J.R. Ashton S.E. Ryan A.J. Blakey D.C. Waterton J.C. Tumour dose response to the antivascular agent zd6126 assessed by magnetic resonance imaging Br. J. Canc. 2003 88 1592 1597 10.1038/sj.bjc.6600926
22. Chang Y.C. Yu C.J. Chen C.M. Hu F.C. Hsu H.H. Tseng W.Y.I. Ting-Fang Shih T. Yang P.C. Chih-Hsin Yang J. Dynamic contrast-enhanced mri in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin J. Magn. Reson. Imag. 2012 36 387 396 10.1002/jmri.23660
23. Hoff B.A. Bhojani M.S. Rudge J. Chenevert T.L. Meyer C.R. Galbán S. Johnson T.D. Leopold J.S. Rehemtulla A. Ross B.D. et al. Dce and dw-mri monitoring of vascular disruption following vegf-trap treatment of a rat glioma model NMR Biomed. 2012 25 935 942 10.1002/nbm.1814
24. Hsu C.Y. Shen Y.C. Yu C.W. Hsu C. Hu F.C. Hsu C.H. Chen B.B. Wei S.Y. Cheng A.L. Shih T.T.F. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil J. Hepatol. 2011 55 858 865 10.1016/j.jhep.2011.01.032
25. Yopp A. Schwartz L. Kemeny N. Gultekin D. Gönen M. Bamboat Z. Shia J. Haviland D. D’Angelica M. Fong Y. et al. Antiangiogenic therapy for primary liver cancer: Correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response Ann. Surg. Oncol. 2011 18 2192 2199 10.1245/s10434-011-1570-1
26. Lemasson B. Christen T. Tizon X. Farion R. Fondraz N. Provent P. Segebarth C. Barbier E.L. Genne P. Duchamp O. et al. Assessment of multiparametric mri in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects NMR Biomed. 2011 24 473 482 10.1002/nbm.1611
27. Heiss W.D. Raab P. Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence J. Nucl. Med. 2011 52 1585 1600 10.2967/jnumed.110.084210
28. Jacobs M.A. Ouwerkerk R. Wolff A.C. Gabrielson E. Warzecha H. Jeter S. Bluemke D.A. Wahl R. Stearns V. Monitoring of neoadjuvant chemotherapy using multiparametric, (2)(3)na sodium mr, and multimodality (pet/ct/mri) imaging in locally advanced breast cancer Breast. Cancer. Res. Treat. 2011 128 119 126 10.1007/s10549-011-1442-1
29. De Bruyne S. van Damme N. Smeets P. Ferdinande L. Ceelen W. Mertens J. van de Wiele C. Troisi R. Libbrecht L. Laurent S. et al. Value of dce-mri and fdg-pet/ct in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases Br. J. Canc. 2012 106 1926 1933 10.1038/bjc.2012.184
30. Viel T. Talasila K.M. Monfared P. Wang J. Jikeli J.F. Waerzeggers Y. Neumaier B. Backes H. Brekka N. Thorsen F. et al. Analysis of the growth dynamics of angiogenesis-dependent and angiogenesis-independent experimental glioblastomas by multimodal small-animal pet and mri J. Nucl. Med. 2012 53 1135 1145 10.2967/jnumed.111.101659
31. Jansen J.F.A. Schöder H. Lee N.Y. Stambuk H.E. Wang Y. Fury M.G. Patel S.G. Pfister D.G. Shah J.P. Koutcher J.A. et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: Pretreatment multimodality imaging with 1 h magnetic resonance spectroscopy, dynamic contrast-enhanced mri, and [18f] fdg-pet Int.J. Radiat. Oncol. Biol. Phys. 2012 82 299 307 10.1016/j.ijrobp.2010.11.022
32. Calamante F. Perfusion mri using dynamic-susceptibility contrast mri: Quantification issues in patient studies Top Magn. Reson. Imag. 2010 21 75 85 10.1097/RMR.0b013e31821e53f5
33. Stanisz G.J. Henkelman R.M. Gd-dtpa relaxivity depends on macromolecular content Magn. Reson. Med. 2000 44 665 667 10.1002/1522-2594(200011)44:5<665::AID-MRM1>3.0.CO;2-M
34. Landis C.S. Li X. Telang F.W. Molina P.E. Palyka I. Vetek G. Springer C.S. Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo Magn. Reson. Med. 1999 42 467 478 10.1002/(SICI)1522-2594(199909)42:3<467::AID-MRM9>3.0.CO;2-0
35. Li X. Priest R.A. Woodward W.J. Tagge I.J. Siddiqui F. Huang W. Rooney W.D. Beer T.M. Garzotto M.G. Springer C.S. Jr. Feasibility of shutter-speed dce-mri for improved prostate cancer detection Magn. Reson. Med. 2012 27 24211
36. Li X. Priest R.A. Woodward W.J. Siddiqui F. Beer T.M. Garzotto M.G. Rooney W.D. Springer C.S. Jr. Cell membrane water exchange effects in prostate dce-mri J. Magn. Reson. 2012 218 77 85
37. Bains L.J. McGrath D.M. Naish J.H. Cheung S. Watson Y. Taylor M.B. Logue J.P. Parker G.J. Waterton J.C. Buckley D.L. Tracer kinetic analysis of dynamic contrast-enhanced mri and ct bladder cancer data: A preliminary comparison to assess the magnitude of water exchange effects Magn. Reson. Med. 2010 64 595 603
38. Buckley D.L. Kershaw L.E. Stanisz G.J. Cellular-interstitial water exchange and its effect on the determination of contrast agent concentration in vivo: Dynamic contrast-enhanced mri of human internal obturator muscle Magn. Reson. Med. 2008 60 1011 1019 10.1002/mrm.21748
39. Caravan P. Strategies for increasing the sensitivity of gadolinium based mri contrast agents Chem. Soc. Rev. 2006 35 512 523 10.1039/b510982p
40. Weinmann H.J. Brasch R.C. Press W.R. Wesbey G.E. Characteristics of gadolinium-dtpa complex: A potential nmr contrast agent AJR Am. J. Roentgenol. 1984 142 619 624
41. Kaewlai R. Abujudeh H. Nephrogenic systemic fibrosis Am. J. Roentgenol. 2012 199 W17 W23 10.2214/AJR.11.8144
42. Wermuth P.J. Jimenez S.A. Gadolinium compounds signaling through tlr 4 and tlr 7 in normal human macrophages: Establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis J. Immunol. 2012 189 318 327 10.4049/jimmunol.1103099
43. Wiesinger B. Kehlbach R. Hemsen J. Bebin J. Bantleon R. Schwenzer N. Spira D. Claussen C.D. Wiskirchen J. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (hsf) as a model for nephrogenic systemic fibrosis Invest. Radiol. 2011 46 71 76 10.1097/RLI.0b013e31820218e9
44. Del Galdo F. Wermuth P.J. Addya S. Fortina P. Jimenez S.A. Nfkappab activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent omniscan: Possible role in the pathogenesis of nephrogenic systemic fibrosis Ann. Rheum. Dis. 2010 69 2024 2033 10.1136/ard.2010.134858
45. Steger-Hartmann T. Raschke M. Riefke B. Pietsch H. Sieber M.A. Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-A mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide Exp. Toxicol. Pathol. 2009 61 537 552 10.1016/j.etp.2008.11.004
46. Sieber M.A. Pietsch H. Walter J. Haider W. Frenzel T. Weinmann H.J. A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media Invest. Radiol. 2008 43 65 75 10.1097/RLI.0b013e31815e6277
47. Rohrer M. Bauer H. Mintorovitch J. Requardt M. Weinmann H.J. Comparison of magnetic properties of mri contrast media solutions at different magnetic field strengths Invest. Radiol. 2005 40 715 724 10.1097/01.rli.0000184756.66360.d3
48. Yang C.T. Chuang K.H. Gd(iii) chelates for mri contrast agents: From high relaxivity to "smart", from blood pool to blood-brain barrier permeable Med.Chem.Comm. 2012 3 552 565 10.1039/c2md00279e
49. Pathak A.P. Penet M.F. Bhujwalla Z.M. MR molecular imaging of tumor vasculature and vascular targets Advances in genetics Renata P. Academic Press 2010 69 1 30
50. Barrett T. Kobayashi H. Brechbiel M. Choyke P.L. Macromolecular mri contrast agents for imaging tumor angiogenesis Eur. J. Radiol. 2006 60 353 366 10.1016/j.ejrad.2006.06.025
51. Kiessling F. Morgenstern B. Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging Curr. Med. Chem. 2007 14 77 91 10.2174/092986707779313516
52. Evelhoch J.L. Key factors in the acquisition of contrast kinetic data for oncology J. Magn. Reson. Imag. 1999 10 254 259 10.1002/(SICI)1522-2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9
53. McIntyre D.J. Robinson S.P. Howe F.A. Griffiths J.R. Ryan A.J. Blakey D.C. Peers I.S. Waterton J.C. Single dose of the antivascular agent, zd6126 (n-acetylcolchinol-o-phosphate), reduces perfusion for at least 96 hours in the gh3 prolactinoma rat tumor model Neoplasia 2004 6 150 157 10.1593/neo.03247
54. Galbraith S.M. Maxwell R.J. Lodge M.A. Tozer G.M. Wilson J. Taylor N.J. Stirling J.J. Sena L. Padhani A.R. Rustin G.J. Combretastatin a4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J. Clin. Oncol. 2003 21 2831 2842
55. Medved M. Karczmar G. Yang C. Dignam J. Gajewski T. Kindler H. Vokes E. Maceneany P. Mitchel M. Stadler W. Semiquantitative analysis of dynamic contrast enhanced mri in cancer patients: Variability and changes in tumor tissue over time J. Magn. Reson. Imag. 2004 20 122 128 10.1002/jmri.20061
56. Mross K. Drevs J. Muller M. Medinger M. Marme D. Hennig J. Morgan B. Lebwohl D. Masson E. Ho Y.Y. et al. Phase i clinical and pharmacokinetic study of ptk/zk, a multiple vegf receptor inhibitor, in patients with liver metastases from solid tumours Eur. J. Canc. 2005 41 1291 1299 10.1016/j.ejca.2005.03.005
57. Hillman G.G. Singh-Gupta V. Zhang H. Al-Bashir A.K. Katkuri Y. Li M. Yunker C.K. Patel A.D. Abrams J. Haacke E.M. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors Neoplasia 2009 11 910 920
58. Marzola P. Degrassi A. Calderan L. Farace P. Nicolato E. Crescimanno C. Sandri M. Giusti A. Pesenti E. Terron A. et al. Early antiangiogenic activity of su11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma Clin. Canc. Res. 2005 11 5827 5832 10.1158/1078-0432.CCR-04-2655
59. Tang J.S. Choy G. Bernardo M. Thomasson D. Libutti S.K. Choyke P.L. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model Investig. Radiol. 2006 41 691 696 10.1097/01.rli.0000233882.83800.fb
60. Checkley D. Tessier J.J. Kendrew J. Waterton J.C. Wedge S.R. Use of dynamic contrast-enhanced mri to evaluate acute treatment with zd6474, a vegf signalling inhibitor, in pc-3 prostate tumours Br. J. Cancer 2003 89 1889 1895 10.1038/sj.bjc.6601386
61. Kuhl C. Mielcareck P. Klaschik S. Leutner C. Wardelmann E. Gieseke J. Schild H. Dynamic breast mr imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions Radiology 1999 211 101 110
62. Fischer U. Kopka L. Grabbe E. Breast carcinoma: Effect of preoperative contrast-enhanced mr imaging on the therapuetic approach Radiology 1999 213 881 888
63. Buadu L. Murakami J. Murayama S. Hashiguchi N. Sakai S. Masuda K. Toyoshima S. Kuroki S. Ohno S. Breast lesions: Correlation of contrast medium enhancement patterns on mr images with histopathologic findings and tumor angiogenesis Radiology 1996 200 639 649
64. Ei Khouli R.H. Jacobs M.A. Mezban S.D. Huang P. Kamel I.R. Macura K.J. Bluemke D.A. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-t breast mr imaging Radiology 2010 256 64 73 10.1148/radiol.10091367
65. Yabuuchi H. Matsuo Y. Okafuji T. Kamitani T. Soeda H. Setoguchi T. Sakai S. Hatakenaka M. Kubo M. Sadanaga N. et al. Enhanced mass on contrast-enhanced breast mr imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted mr images J. Magn. Reson.Imag. 2008 28 1157 1165 10.1002/jmri.21570
66. Qayyum A. Birdwell R.L. Daniel B.L. Nowels K.W. Jeffrey S.S. Agoston T.A. Herfkens R.J. Mr imaging features of infiltrating lobular carcinoma of the breast: Histopathologic correlation Am. J. Roentgenol. 2002 178 1227 1232
67. Weinstein S.P. Orel S.G. Heller R. Reynolds C. Czerniecki B. Solin L.J. Schnall M. Mr imaging of the breast in patients with invasive lobular carcinoma Am. J. Roentgenol. 2001 176 399 406
68. Orel S.G. Schnall M.D. LiVolsi V.A. Troupin R.H. Suspicious breast lesions: Mr imaging with radiologic-pathologic correlation Radiology 1994 190 485 493
69. Buadu L.D. Murakami J. Murayama S. Hashiguchi N. Sakai S. Toyoshima S. Masuda K. Kuroki S. Ohno S. Patterns of peripheral enhancement in breast masses: Correlation of findings on contrast medium enhanced mri with histologic features and tumor angiogenesis J. Comput. Assist. Tomo. 1997 21 421 430 10.1097/00004728-199705000-00016
70. Galbraith S.M. Lodge M.A. Taylor N.J. Rustin G.J.S. Bentzen S. Stirling J.J. Padhani A.R. Reproducibility of dynamic contrast-enhanced mri in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis NMR Biomed. 2002 15 132 142 10.1002/nbm.731
71. Kety S.S. The theory and applications of the exchange of inert gas at the lungs and tissues Pharmacol. Rev. 1951 3 1 41
72. Shames D.M. Kuwatsuru R. Vexler V. Mühler A. Brasch R.C. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: A quantitative noninvasive technique Magn. Reson. Med. 1993 29 616 622 10.1002/mrm.1910290506
73. Faranesh A.Z. Kraitchman D.L. McVeigh E.R. Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent Magn. Reson. Med. 2006 55 1114 1123 10.1002/mrm.20884
74. Daldrup H. Shames D. Wendland M. Okuhata Y. Link T. Rosenau W. Lu Y. Brasch R. Correlation of dynamic contrast-enhanced mr imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media Am. J. Roentgenol. 1998 171 941 949
75. Bradley D.P. Tessier J.L. Checkley D. Kuribayashi H. Waterton J.C. Kendrew J. Wedge S.R. Effects of azd2171 and vandetanib (zd6474, zactima) on haemodynamic variables in an sw620 human colon tumour model: An investigation using dynamic contrast-enhanced mri and the rapid clearance blood pool contrast agent, p792 (gadomelitol) NMR Biomed. 2008 21 42 52 10.1002/nbm.1161
76. Wedge S.R. Kendrew J. Hennequin L.F. Valentine P.J. Barry S.T. Brave S.R. Smith N.R. James N.H. Dukes M. Curwen J.O. et al. Azd2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Canc. Res. 2005 65 4389 4400
77. Luo Y. Jiang F. Cole T. Hradil V. Reuter D. Chakravartty A. Albert D. Davidsen S. Cox B. McKeegan E. et al. A novel multi-targeted tyrosine kinase inhibitor, linifanib (abt-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model Cancer Chemotherapy and Pharmacology 2012 69 911 921 10.1007/s00280-011-1740-7
78. Nielsen T. Murata R. Maxwell R.J. Stødkilde-Jørgensen H. Østergaard L. Horsman M.R. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients International Journal of Radiation Oncology*Biology*Physics 2008 70 859 866 10.1016/j.ijrobp.2007.10.012
79. Kingsley P.B. Methods of measuring spin-lattice (t1) relaxation times: An annotated bibliography Concepts Magn. Reson. 1999 11 243 276 10.1002/(SICI)1099-0534(1999)11:4<243::AID-CMR5>3.0.CO;2-C
80. Guilfoyle D.N. Dyakin V.V. O’Shea J. Pell G.S. Helpern J.A. Quantitative measurements of proton spin-lattice (t1) and spin-spin (t2) relaxation times in the mouse brain at 7.0 t Magn. Reson. Med. 2003 49 576 580 10.1002/mrm.10371
81. Loveless M.E. Halliday J. Liess C. Xu L. Dortch R.D. Whisenant J. Waterton J.C. Gore J.C. Yankeelov T.E. A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-mri in small animals Magn. Reson. Med. 2012 67 226 236 10.1002/mrm.22988
82. Haase A. Frahm J. Matthaei D. Hanicke W. Merboldt K.D. Flash imaging. Rapid nmr imaging using low flip-angle pulses J. Magn. Reson. 1986 67 258 266
83. Haacke M. Brown R. Thompson M. Venkatesan R. Magnetic Resonance Imaging: Physical Principles and Sequence Design Wiley-Liss Hoboken, NJ, USA 1999
84. Loveless M.E. Whisenant J.G. Wilson K. Lyshchik A. Sinha T.K. Gore J.C. Yankeelov T.E. Coregistration of ultrasonography and magnetic resonance imaging with a preliminary investigation of the spatial colocalization of vascular endothelial growth factor receptor 2 expression and tumor perfusion in a murine tumor model Mol. Imag. 2009 8 187 198
85. Yankeelov T.E. Niermann K.J. Huamani J. Kim D.W. Quarles C.C. Fleischer A.C. Hallahan D.E. Price R.R. Gore J.C. Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging J. Ultrasound. Med. 2006 25 487 497
86. Yankeelov T.E. Gore J.C. Dynamic contrast enhanced magnetic resonance imaging in oncology: Theory, data acquisition, analysis, and examples Curr. Med. Imag. Rev. 2009 3 91 107 10.2174/157340507780619179
87. Hornak J.P. Szumowski J. Bryant R.G. Magnetic field mapping Magn. Reson. Med. 1988 6 158 163 10.1002/mrm.1910060204
88. Yarnykh V.L. Actual flip-angle imaging in the pulsed steady state: A method for rapid three-dimensional mapping of the transmitted radiofrequency field Magn. Reson. Med. 2007 57 192 200 10.1002/mrm.21120
89. Loveless M.E. Lawson D. Collins M. Nadella M.V. Reimer C. Huszar D. Halliday J. Waterton J.C. Gore J.C. Yankeelov T.E. Comparisons of the efficacy of a jak 1/2 inhibitor (azd 1480) with a vegf signaling inhibitor (cediranib) and sham treatments in mouse tumors using dce-mri, dw-mri, and histology Neoplasia 2012 14 54 64
90. Benjaminsen I.C. Graff B.A. Brurberg K.G. Rofstad E.K. Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced mri: A preclinical study of human melanoma xenografts Magn. Reson. Med. 2004 52 269 276 10.1002/mrm.20149
91. Kim H. Folks K. Guo L. Stockard C. Fineberg N. Grizzle W. George J. Buchsbaum D. Morgan D. Zinn K. Dce-mri detects early vascular response in breast tumor xenografts following anti-dr5 therapy Mol. Imag. Biol. 2011 13 94 103 10.1007/s11307-010-0320-2
92. Li X. Rooney W.D. Várallyay C.G. Gahramanov S. Muldoon L.L. Goodman J.A. Tagge I.J. Selzer A.H. Pike M.M. Neuwelt E.A. et al. Dynamic-contrast-enhanced-mri with extravasating contrast reagent: Rat cerebral glioma blood volume determination J. Magn. Reson. 2010 206 190 199
93. Skinner J. Yankeelov T.E. Peterson T. Does M. Comparison of dynamic contrast enhanced mri and quantitative spect in a rat glioma model Contrast Media Mol. Imag. 2012 in press
94. Kim J.H. Im G.H. Yang J. Choi D. Lee W.J. Lee J.H. Quantitative dynamic contrast-enhanced mri for mouse models using automatic detection of the arterial input function NMR Biomed. 2012 25 674 684 10.1002/nbm.1784
95. Yankeelov T.E. Luci J.J. Lepage M. Li R. Debusk L. Lin P.C. Price R.R. Gore J.C. Quantitative pharmacokinetic analysis of dce-mri data without an arterial input function: A reference region model Magn. Reson. Imag. 2005 23 519 529 10.1016/j.mri.2005.02.013
96. Fritz-Hansen T. Rostrup E. Larsson H.B. Sondergaard L. Ring P. Henriksen O. Measurement of the arterial concentration of gd-dtpa using mri: A step toward quantitative perfusion imaging Magn. Reson. Med. 1996 36 225 231 10.1002/mrm.1910360209
97. Van Osch M.J.P. Vonken E.-j.P.A. Viergever M.A. van der Grond J. Bakker C.J.G. Measuring the arterial input function with gradient echo sequences Magn. Reson. Med. 2003 49 1067 1076 10.1002/mrm.10461
98. Port R.E. Knopp M.V. Hoffmann U. Milker-Zabel S. Brix G. Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic mr imaging J. Magn. Reson. Med. 1999 10 233 241
99. Port R.E. Knopp M.V. Brix G. Dynamic contrast-enhanced mri using gd-dtpa: Interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors Magn. Reson. Med. 2001 45 1030 1038 10.1002/mrm.1137
100. Parker G.J. Barker G.J. Tofts P.S. Accurate multislice gradient echo t (1) measurement in the presence of non-ideal rf pulse shape and rf field nonuniformity Magn. Reson. Med. 2001 45 838 845 10.1002/mrm.1112
101. Parker G.J.M. Roberts C. Macdonald A. Buonaccorsi G.A. Cheung S. Buckley D.L. Jackson A. Watson Y. Davies K. Jayson G.C. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced mri Magn. Reson. Med. 2006 56 993 1000 10.1002/mrm.21066
102. McGrath D.M. Bradley D.P. Tessier J.L. Lacey T. Taylor C.J. Parker G.J.M. Comparison of model-based arterial input functions for dynamic contrast-enhanced mri in tumor bearing rats Magn. Reson. Med. 2009 61 1173 1184 10.1002/mrm.21959
103. Li X. Welch E.B. Arlinghaus L.R. Chakravarthy A.B. Xu L. Farley J. Loveless M.E. Mayer I.A. Kelley M.C. Meszoely I.M. et al. A novel aif tracking method and comparison of dce-mri parameters using individual and population-based aifs in human breast cancer Phys. Med. Biol. 2011 56 5753 5769 10.1088/0031-9155/56/17/018
104. Pickup S. Zhou R. Glickson J. Mri estimation of the arterial input function in mice Acad. Radiol. 2003 10 963 968 10.1016/S1076-6332(03)00291-5
105. Kovar D.A. Lewis M. Karczmar G.S. A new method for imaging perfusion and contrast extraction fraction: Input functions derived from reference tissues J. Magn. Reson. Imag. 1998 8 1126 1134 10.1002/jmri.1880080519
106. Yang C. Karczmar G.S. Medved M. Stadler W.M. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced mri studies: Fundamental concepts and simulations Magn. Reson. Med. 2004 52 1110 1117 10.1002/mrm.20243
107. Heisen M. Fan X. Buurman J. van Riel V. Karczmar G. ter Haar Romeny B. The use of a reference tissue arterial input function with low-temporal-resolution dce-mri data Phys. Med. Biol. 2010 55 4871 4883 10.1088/0031-9155/55/16/016
108. Yankeelov T.E. Cron G.O. Addison C.L. Wallace J.C. Wilkins R.C. Pappas B.A. Santyr G.E. Gore J.C. Comparison of a reference region model with direct measurement of an aif in the analysis of dce-mri data Magn. Reson. Med. 2007 57 353 361 10.1002/mrm.21131
109. Yankeelov T.E. DeBusk L.M. Billheimer D.D. Luci J.J. Lin P.C. Price R.R. Gore J.C. Repeatability of a reference region model for analysis of murine dce-mri data at 7 t J. Magn. Reson. Imag. 2006 24 1140 1147 10.1002/jmri.20729
110. Walker-Samuel S. Parker C.C. Leach M.O. Collins D.J. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: Comparison with a fixed vascular input function Phys. Med. Biol. 2007 52 75 89 10.1088/0031-9155/52/1/006
111. Padhani A.R. Hayes C. Landau S. Leach M.O. Reproducibility of quantitative dynamic mri or normal human tissues NMR Biomed. 2001 15 143 153
112. Morgan B. Utting J.F. Higginson A. Thomas A.L. Steward W.P. Horsfield M.A. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced mr imaging Br. J. Cancer 2006 94 1420 1427 10.1038/sj.bjc.6603140
113. Barnes S. Whisenant J. Loveless M. Ayers G. Yankeelov T. Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer Magn. Reson. Med. 2012 10.1002/mrm.24422
114. Fueger B.J. Czernin J. Hildebrandt I. Tran C. Halpern B.S. Stout D. Phelps M.E. Weber W.A. Impact of animal handling on the results of 18f-fdg pet studies in mice J. Nucl. Med. 2006 47 999 1006
115. Norris D.G. High field human imaging J. Magn. Reson. Imag. 2003 18 519 529 10.1002/jmri.10390
116. Padhani A.R. Liu G. Koh D.M. Chenevert T.L. Thoeny H.C. Takahara T. Dzik-Jurasz A. Ross B.D. Van Cauteren M. Collins D. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations Neoplasia 2009 11 102 125
117. Cheng H.-L.M. Wallis C. Shou Z. Farhat W.A. Quantifying angiogenesis in vegf-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced mri using contrast agents of different molecular weights J. Magn. Reson. Imag. 2007 25 137 145 10.1002/jmri.20787
118. Ren J. Huan Y. Wang H. Chang Y.J. Zhao H.T. Ge Y.L. Liu Y. Yang Y. Dynamic contrast-enhanced mri of benign prostatic hyperplasia and prostatic carcinoma: Correlation with angiogenesis Clin. Radiol. 2008 63 153 159 10.1016/j.crad.2007.07.023
119. Hulka C.A. Edmister W.B. Smith B.L. Tan L. Sgroi D.C. Campbell T. Kopans D.B. Weisskoff R.M. Dynamic echo-planar imaging of the breast: Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis Radiology 1997 205 837 842
120. Yao W.W. Zhang H. Ding B. Fu T. Jia H. Pang L. Song L. Xu W. Song Q. Chen K. et al. Rectal cancer: 3 d dynamic contrast-enhanced mri; correlation with microvascular density and clinicopathological features Radiol. Med. 2011 116 366 374 10.1007/s11547-011-0628-2
121. Haris M. Husain N. Singh A. Awasthi R. Singh Rathore R.K. Husain M. Gupta R.K. Dynamic contrast-enhanced (dce) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (mmp-9) expression in brain tuberculomas J. Magn. Reson. Imag. 2008 28 588 597 10.1002/jmri.21491
122. Orth R.C. Bankson J. Price R. Jackson E.F. Comparison of single-tracer and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced mri data using low, medium, and high molecular weight contrast agents Magn. Reson. Med. 2007 58 705 716 10.1002/mrm.21411
123. Reitan N.K. Thuen M. Goa P.E. Davies C.D.L. Characterization of tumor microvascular structure and permeability: Comparison between magnetic resonance imaging and intravital confocal imaging J. Biomed. Optics 2010 15 036004 10.1117/1.3431095
124. Mayr N.A. Hawighorst H. Yuh W.T.C. Essig M. Magnotta V.A. Knopp M.V. Mr microcirculation assessment in cervical cancer: Correlations with histomorphological tumor markers and clinical outcome J. Magn. Reson. Imag. 1999 10 267 276 10.1002/(SICI)1522-2586(199909)10:3<267::AID-JMRI7>3.0.CO;2-Y
125. Egeland T.A.M. Simonsen T.G. Gaustad J.V. Gulliksrud K. Ellingsen C. Rofstad E.K. Dynamic contrast-enhanced magnetic resonance imaging of tumors: Preclinical validation of parametric images Radiat. Res. 2009 172 339 347 10.1667/RR1787.1
126. Aref M. Chaudhari A.R. Bailey K.L. Aref S. Wiener E.C. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates Magn. Reson. Imag. 2008 26 1279 1293 10.1016/j.mri.2008.02.015
127. Sinha T.K. Khatib-Shahidi S. Yankeelov T.E. Mapara K. Ehtesham M. Cornett D.S. Dawant B.M. Caprioli R.M. Gore J.C. Integrating spatially resolved three-dimensional maldi ims with in vivo magnetic resonance imaging Nat. Meth. 2008 5 57 59 10.1038/nmeth1147
128. Meyer C.R. Moffat B.A. Kuszpit K.K. Bland P.L. McKeever P.E. Johnson T.D. Chenevert T.L. Rehemtulla A. Ross B.D. A methodology for registration of a histological slide and in vivo mri volume based on optimizing mutual information Mol. Imag. 2006 5 16 23
129. Zanzonico P.B. Broad-spectrum multi-modality image registration: From pet, ct, and mri to autoradiography, microscopy, and beyond Conf. Proc. IEEE Eng. Med. Biol. Soc. 2006 1 1584 1588
130. Naish J.H. McGrath D.M. Bains L.J. Passera K. Roberts C. Watson Y. Cheung S. Taylor M.B. Logue J.P. Buckley D.L. et al. Comparison of dynamic contrast-enhanced mri and dynamic contrast-enhanced ct biomarkers in bladder cancer Magn. Reson. Med. 2011 66 219 226 10.1002/mrm.22774
131. Korporaal J.G. van den Berg C.A. van Osch M.J. Groenendaal G. van Vulpen M. van der Heide U.A. Phase-based arterial input function measurements in the femoral arteries for quantification of dynamic contrast-enhanced (dce) mri and comparison with dce-ct Magn. Reson. Med. 2011 66 1267 1274 10.1002/mrm.22905
132. Kierkels R.G.J. Backes W.H. Janssen M.H.M. Buijsen J. Beets-Tan R.G.H. Lambin P. Lammering G. Oellers M.C. Aerts H.J.W.L. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer Int. J. Radiat. Oncol. Biol. Phys. 2010 77 400 408 10.1016/j.ijrobp.2009.05.015
133. Ng C.S. Waterton J.C. Kundra V. Brammer D. Ravoori M. Han L. Wei W. Klumpp S. Johnson V.E. Jackson E.F. Reproducibility and comparison of dce-mri and dce-ct perfusion parameters in a rat tumor model Tech. Canc. Res. Treat. 2012 11 279 288
134. Donahue K.M. Weisskoff R.M. Parmelee D.J. Callahan R.J. Wilkinson R.A. Mandeville J.B. Rosen B.R. Dynamic gd-dtpa enhanced mri measurement of tissue cell volume fraction Magn. Reson. Med. 1995 34 423 432 10.1002/mrm.1910340320
135. Pellerin M. Yankeelov T.E. Lepage M. Incorporating contrast agent diffusion into the analysis of dce-mri data Magn. Reson. Med. 2007 58 1124 1134 10.1002/mrm.21400
136. Einstein A. Über die von der molekularkinetischen theorie der wärme geforderte bewegung von in ruhenden flüssigkeiten suspendierten teilchen Ann. Phys. 1905 322 549 560 10.1002/andp.19053220806
137. Anderson A.W. Xie J. Pizzonia J. Bronen R.A. Spencer D.D. Gore J.C. Effects of cell volume fraction changes on apparent diffusion in human cells Magn. Reson. Imag. 2000 18 689 695 10.1016/S0730-725X(00)00147-8
138. Yankeelov T.E. Lepage M. Chakravarthy A. Broome E.E. Niermann K.J. Kelley M.C. Meszoely I. Mayer I.A. Herman C.R. McManus K. et al. Integration of quantitative dce-mri and adc mapping to monitor treatment response in human breast cancer: Initial results Magn. Reson. Imag. 2007 25 1 13
139. Mills S.J. Soh C. Rose C.J. Cheung S. Zhao S. Parker G.J.M. Jackson A. Candidate biomarkers of extravascular extracellular space: A direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced mr imaging-Derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme Am. J. Neuroradiol. 2010 31 549 553 10.3174/ajnr.A1844
140. Arlinghaus L.R. Li X. Rahman A.R. Welch E.B. Xu L. Gore J.C. Yankeelov T.E. On the relationship between the apparent diffusion coefficient and extravascular extracellular volume fraction in human breast cancer Magn. Reson. Imag. 2011 29 630 638 10.1016/j.mri.2011.02.004
141. Dunphy M.P.S. Lewis J.S. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with pet J. Nucl. Med. 2009 50 106 121 10.2967/jnumed.108.057281
142. Dearling J. Lewis J. Mullen G. Welch M. Blower P. Copper bis (thiosemicarbazone) complexes as hypoxia imaging agents: Structure-activity relationships J. Biol. Inorg. Chem. 2002 7 249 259 10.1007/s007750100291
143. Lewis J.S. Welch M.J. Pet imaging of hypoxia Q. J. Nucl. Med. Mol. Imag. 2001 45 183 188
144. Cho H. Ackerstaff E. Carlin S. Lupu M.E. Wang Y. Rizwan A. O’Donoghue J. Ling C.C. Humm J.L. Zanzonico P.B. et al. Noninvasive multimodality imaging of the tumor microenvironment: Registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia Neoplasia 2009 11 247 259
145. Coleman C.N. Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity J. Natl. Canc. Inst. 1988 80 310 317 10.1093/jnci/80.5.310
146. Jansen J.F. Schoder H. Lee N.Y. Wang Y. Pfister D.G. Fury M.G. Stambuk H.E. Humm J.L. Koutcher J.A. Shukla-Dave A. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18 f-fluoromisonidazole positron emission tomography imaging in neck nodal metastases Int. J. Radiat. Oncol. Biol. Phys. 2010 77 1403 1410 10.1016/j.ijrobp.2009.07.009
147. Shaw R.J. Glucose metabolism and cancer Curr. Opin. Cell. Biol. 2006 18 598 608 10.1016/j.ceb.2006.10.005
148. Metz S. Ganter C. Lorenzen S. van Marwick S. Herrmann K. Lordick F. Nekolla S.G. Rummeny E.J. Wester H.J. Brix G. et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: Relationship of microcirculation, αvβ3 expression, and glucose metabolism J. Nucl. Med. 2010 51 1691 1698 10.2967/jnumed.110.077719
149. Partridge S.C. Vanantwerp R.K. Doot R.K. Chai X. Kurland B.F. Eby P.R. Specht J.M. Dunnwald L.K. Schubert E.K. Lehman C.D. et al. Association between serial dynamic contrast-enhanced mri and dynamic 18 f-fdg pet measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer J. Mag. Reson. Imag. 2010 32 1124 1131 10.1002/jmri.22362
150. Huang J. Chunta J.L. Amin M. Lee D.Y. Grills I.S. Wong C.Y. Yan D. Marples B. Martinez A.A. Wilson G.D. Detailed characterization of the early response of head-neck cancer xenografts to irradiation using (18) f-fdg-pet imaging Int. J. Radiat. Oncol. Biol. Phys. 2012 11 11
151. Mani S. Chen Y. Arlinghaus L. Li X. Chakravarthy A. Bhave S. Welch E.B. Levy M. Yankeelov T.E. Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative mri and machine learning AMIA Annu. Symp. Proc. 2011 868 877
152. Cheebsumon P. Velasquez L. Hoekstra C. Hayes W. Kloet R. Hoetjes N. Smit E. Hoekstra O. Lammertsma A. Boellaard R. Measuring response to therapy using fdg pet: Semi-quantitative and full kinetic analysis Eur. J. Nucl. Med. Mol. Imag. 2011 38 832 842 10.1007/s00259-010-1705-9
153. Braren R. Altomonte J. Settles M. Neff F. Esposito I. Ebert O. Schwaiger M. Rummeny E. Steingoetter A. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization J. Hepatol. 2011 55 1034 1040 10.1016/j.jhep.2011.01.049
154. Sala E. Kataoka M.Y. Priest A.N. Gill A.B. McLean M.A. Joubert I. Graves M.J. Crawford R.A.F. Jimenez-Linan M. Earl H.M. et al. Advanced ovarian cancer: Multiparametric mr imaging demonstrates response- and metastasis-specific effects Radiology 2012 263 149 159 10.1148/radiol.11110175
155. Brix G. Semmler W. Port R.E. Schad L.R. Layer G. Lorenz W.J. Pharmacokinetic parameters in cns gd-dtpa enhanced mr imaging J. Comput. Assist. Tomo. 1991 15 621 628 10.1097/00004728-199107000-00018
156. Larsson H.B.W. Stubgard M. Frederiksen J.L. Jensen M. Henriksen O. Paulson O.B. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-dtpa in patients with multiple sclerosis and brain tumors Magn. Reson. Med. 1990 16 117 131 10.1002/mrm.1910160111
157. Tofts P.S. Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic mr imaging. 1. Fundamental concepts Magn. Reson. Med. 1991 17 357 367 10.1002/mrm.1910170208
158. Donahue M. Blakeley J. Zhou J. Pomper M. Laterra J. van Zijl P. Evaluation of human brain tumor heterogeneity using mutliple t 1-based mri signal weighting approaches Magn. Reson. Med. 2008 59 336 344 10.1002/mrm.21467
159. Jia G. O’Dell C. Heverhagen J. Xang X. Liang J. Jacko R. Sammet S. Pellas T. Cole P. Knopp M.V. Colorectal liver metastases: Contrast agent diffusion coefficient for quantification of contrast enhancement heterogeneity at mr imaging Radiology 2008 248 901 909 10.1148/radiol.2491071936
160. Landis C. Li X. Telang F. Coderre J. Micca P. Rooney W. Latour L. Vetek G. Palyka I. Springer C.S. Jr. Determination of the mri contrast agent concentration time course in vivo following bolus injection: Effect of equilibrium transcytolemmal water exchange Magn. Reson. Med. 2000 44 563 574 10.1002/1522-2594(200010)44:4<563::AID-MRM10>3.0.CO;2-#
161. Yankeelov T.E. Rooney W.D. Huang W. Dyke J.P. Li X. Tudorica A. Lee J.H. Koutcher J.A. Springer C.S. Evidence for shutter-speed variation in cr bolus-tracking studies of human pathology NMR Biomed. 2005 18 173 185 10.1002/nbm.938
162. Yankeelov T.E. Rooney W.D. Li X. Springer C.S. Jr. Variation of the relaxographic “shutter-speed” for transcytolemmal water exchange affects the cr bolus-tracking curve shape Magn. Reson. Med. 2003 50 1151 1169 10.1002/mrm.10624
163. Li X. Huang W. Yankeelov T.E. Tudorica A. Rooney W.D. Springer C.S. Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease Magn. Reson. Med. 2005 53 724 729 10.1002/mrm.20405
164. Zhou R. Pickup S. Yankeelov T.E. Springer C.S. Jr. Glickson J.D. Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: Effects of transcytolemmal water exchange Magn. Reson. Med. 2004 52 248 257 10.1002/mrm.20143
165. Donahue K.M. Weisskoff R.M. Burstein D. Water diffusion and exchange as they influence contrast enhancement J. Magn. Reson. Imag. 1997 7 102 110 10.1002/jmri.1880070114
166. McConnell H.M. Reaction rates by nuclear magnetic resonance J. Chem. Phys. 1958 28 430 431 10.1063/1.1744152
167. Woessner D.E. Nuclear transfer effects in nuclear magnetic resonance pulse experiments J. Chem. Phys. 1961 35 41 48 10.1063/1.1731931
168. Huang W. Tudorica L.A. Li X. Thakur S.B. Chen Y. Morris E.A. Tagge I.J. Korenblit M.E. Rooney W.D. Koutcher J.A. et al. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced mr imaging Radiology 2011 261 394 403 10.1148/radiol.11102413